Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: An early marker of diabetic kidney disease?

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 6, 2008, Pages 667-676

  Hutchison, Colin A ^a,b   Cockwell, Paul ^a,b   Harding, Steven ^c   Mead, Graham P ^c   Bradwell, Arthur R ^b,d   Barnett, Anthony H ^b,d  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c Binding Site Group Ltd   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biomarker; Diabetic kidney disease; Free light chains; Type II diabetis

Indexed keywords

ALBUMIN; BIOCHEMICAL MARKER; CREATININE; CYSTATIN C; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; ASIAN; CAUCASIAN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; EARLY DIAGNOSIS; ETHNIC DIFFERENCE; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; SOUTH ASIA; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED;

EID: 45849124598     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.6.667     Document Type: Article

References (48)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414(6865):782-7
2. KDOQI working group. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease: executive summary. Am J Kidney Dis 2007;49(Suppl 2):S13-9
3. KDOQI working group. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease: background. Am J Kidney Dis 2007;49(Suppl 2):S21-41
4. Dineen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157:1413-8
5. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63(1):225-32
6. Miettinen H, Haffer SM, Lehto S, et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033-9
7. Valmadrid CT, Mein R, Moss SE, Mein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000;160:1093-100
8. Gaede P, Vedel P, Parving HH, Pedersen O. Intensive multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The steno type2 randomised study. Lancet 1999;353:617-22
9. KDOQI working group. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease': screening and diagnosis of diabetic kidney disease. Am J Kidney Dis 2007;49(Suppl 2):S42-61
10. KDOQI working group. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease: research recommendations. Am J Kidney Dis 2007;49(Suppl 2):S140-3
11. Bradwell AR. 'Biology of immunoglobulin light chains'. In: Serum free light chain analysis. 4th edition. The Binding Site Ltd, Birmingham; 2006. p. 12-20
12. Bradwell AR. 'Diseases with increased polyclonal free light chains'. In: Serum free light chain analysis. 4th edition. The Binding Site Ltd, Birmingham; 2006. p. 173-83
13. O'Hare JP, Raymond NT, Mughal S, et al. Evaluation of delivery of enhanced diabetes care to patients of South Asian ethnicity: the United Kingdom Asian Diabetes Study (UKADS). Diabetic Med 2004;21(12):1357-65
14. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44
15. Tencer J, Thysell H, Andersson K, Grubb A. Long-term stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain-immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at -20 degrees C. Scand J Urol Nephrol 1997;31(1):67-71
16. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive automated immunoassay for immunoglobulin FLCs in serum and urine. Clin Chem 2001;47:673-80
17. Vervoort GH, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 2002; 17(11):1909-13
18. Levey AS, Coresh J, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2002;139(2):137-47
19. van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006;533(1-3):319-26
20. Solling K, Solling J, Romer FK. Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med Scand 1981;209(6):473-7
21. Streja D, Cressey P, Rabkin SW. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 2003;17(3):120-7
22. Festa. A, D'Agostino R, Howard G, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000;58(4):1703-10
23. Poggio ED, Wang X, Greene T, et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005;16(2):459-66
24. Froissart M, Rossert J, Jacquot C, et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimaiting renal function. J Am Soc Nephrol 2005;16(3):763-73
25. Rigalleau V, Lasseur C, Perlemoine C, et al. Cockcroft-Gault formula is biased by body weight in diabetic patients with renal impairment. Metabolism 2006;55(1):108-12
26. Rigalleau. V, Lasseur C, Perlemoine C, et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of diet in renal disease study equation? Diabetes Care 2005;28(4):838-43
27. de Boer IH, Steffes MW. Glomerular filtration rate and albuminuria: twin manifestations of nephropathy in diabetes. J Am Soc Nephrol 2007; 18:1036-7
28. Wang PX, Sanders PW. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol 2007;18(4):1239-45
29. Teppo A, Groop L, Urinary excretion of plasma proteins in diabetic subjects. Increased excretion of kappa light chains in diabetic patients with and without proliferative rerinopathy. Diabetes 1985;34(6):589-94
30. Yu Y, Suo L, et al. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria Diabetes Res Clin Pract 2004;65(2):95-104
31. Mathiesen ER, Ronn B, Storm B, et al. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med 1995;12:482-7
32. MacLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia 1995;38(5):610-6
33. Collins VR, Dowse GK, Finch CF, et al. Prevalence and risk factors for micro- and macroalbuminuria in diabetic subjects and entire population of Nauru. Diabetes 1989;38(12):1602-10
34. Nelson RG, Kunzelamn CL, Pettitt DJ, et al. Albuminuria in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia 1989;32:870-6
35. Simmons D, Shaw L, Scott DJ, et al. Diabetic nephropathy and microalbuminuria in the community. The South Auckland Diabetes Survey. Diabetes Care 1994;17:1404-10
36. Groop L, Makipernaa A, Stenman, et al. Urinary excretion of kappa light chains in patients with diabetes mellitus. Kidney Int 1990;(37):1120-5
37. Klassen R, Allen PL, Baruman V, et al. Light chains are a ligand for megalin. J Appl Physiol 2005;98(1):257-63
38. Batuman V, Verroust PJ, Navar GL, et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol Renal Physiol 1998;275(2):F246-54
39. Cutillas PR, Chalkley RJ, Hansen KC, et al. The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by Renal proximal tubule cells. Am J Physiol Renal Physiol 2004;287(3):F353-64
40. Somani R, Grant PJ, Kain K, et al. Complement C3 and C-reactive protein are elevated in South Asians independent of a family history of stroke. Stroke 2006;37(8):2001-6
41. Lip GY, Barnett AH, Bradbury A, et al. Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. J Hum Hypertens 2007;21(3):183-211
42. Williams R, Bhopal R, Hunt K. Coronary risk in a British Punjabi population: comparative profile of non-biochemical factors. IntJ Epidemiol 1994;23(1):28-37
43. Chandie Shaw PK, Berger SP, Mallat M, et al. Central obesity is an independent risk factor for albuminuria in "non-diabetic" South Asian subjects. Diabetes Care 2007;7-28
44. Joshi P, Islam S, Pais P et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 2007;297(17):1880-1
45. Eriksson M. Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur J Cancer 1993;29A(2):259-63
46. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C Virus infection. Ann Intern Med 1998;129(4):294-8
47. Kyle R, Therneau TM, Rajkumar S, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354(13):1362-9
48. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992;6(2):225-47